Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma

Posted on October 22nd, 2009 by Kelley Luckstein

High-dose dexamethasone is a mainstay of therapy for multiple myeloma. We studied whether low-dose dexamethasone in combination with lenalidomide is non-inferior to and has lower toxicity than high-dose dexamethasone plus lenalidomide…

 

Lenalidomide plus low-dose dexamethasone is associated with better short-term overall survival and with lower toxicity than lenalidomide plus high-dose dexamethasone in patients with newly diagnosed myeloma.

 

Study published by Dr. S. Vincent Rajkumar in The Lancet Oncology, 10/22/09

 

Read more on the Mayo Clinic News blog.

Tags: dexamethasone, Hematology, oncology

You must be logged-in to the site to post a comment.

Contact Us · Privacy Policy